clinical trial · NCT01298323
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Locally Advanced or Metastatic Medullary Thyroid CancerMedullary Thyroid CancerPatient outreachVandetanib
brief summary
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
started
Feb 25, 2011
primary completion
Apr 26, 2013
completion
Mar 13, 2025
last updated
Apr 17, 2026
official title
A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol